Search Results

All Content Formulary Only Other Content

Scottish Formulary has compiled the following search results: We have found 54 results when searching "Pembrolizumab"

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2644 : In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or ga...

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2660 : In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-...

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2689 : As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy. SMC r...

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2688 : In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung ca...

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2767 : In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2915 : In combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.

FORMULARY DECISION

Pembrolizumab : Keytruda

SMC2829 : In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults w...

FORMULARY DECISION

Pembrolizumab : Keytruda

1086/15 : As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously untreated with ipilimumab.

FORMULARY DECISION

Pembrolizumab : Keytruda

1087/15 : As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.

FORMULARY DECISION

Pembrolizumab : Keytruda

1204/17 : The treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one pri...